Shilpa Medicare marketing partner Amneal Pharma unveils multiple myeloma treatment Boruzu

This product references the branded product Velcade, a lyophilized powder requiring reconstitution before use.   

Shilpa developed the molecule and Amneal will manufacture and commercialize the product.                                                                   

Read also: Shilpa Medicare receives European marketing authorization for Tadalafil Orodispersible Films for erectile dysfunction  

“This is the second NDA product being launched in the US market from our novel injectable portfolio demonstrates our capabilities and commitment to introduce pharmacy efficient solutions that enhance compliance and have the potential to reduce patient wait times. This development exemplifies Shilpa’s constant endeavor to work towards introducing novel first of its kind pharmaceutical products that help improve the healthcare requirements of a large patient pool,” said Vishnukant Bhutada, Managing Director of Shilpa Medicare.   

Read also: Shilpa Medicare Gets CDSCO Panel Nod for Novel NAFLD Drug, Advances to Marketing Approval Stage

The Company is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including novel injectables, orally dispersible films & transdermal patches along with carefully crafted biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.      

Read also: Shilpa Medicare gets CDSCO panel nod to conduct Phase III clinical trials for Recombinant Human Albumin 20%